Compare APT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | LUNG |
|---|---|---|
| Founded | 1983 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 57.9M |
| IPO Year | 1997 | 2020 |
| Metric | APT | LUNG |
|---|---|---|
| Price | $5.59 | $1.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 55.3K | ★ 568.9K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.07 | N/A |
| Revenue | $59,142,000.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $78.57 | ★ N/A |
| Revenue Growth | 2.25 | ★ 8.01 |
| 52 Week Low | $4.34 | $1.13 |
| 52 Week High | $7.50 | $3.88 |
| Indicator | APT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 50.96 |
| Support Level | $5.49 | $1.22 |
| Resistance Level | $5.64 | $1.45 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 61.97 | 53.12 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.